Menu
Recruiting NCT04920318

Enhancing Language Function in Primary Progressive Aphasia

No phase Interventional Primary Progressive Aphasia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: tDCS + language therapy, sham TDCS + language therapy.
Who it may be relevant to
Registry conditions: Primary Progressive Aphasia. Basic parameters: 45 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Enhancing Language Function in Primary Progressive Aphasia (PPA) With Transcranial Direct Current Stimulation (tDCS)

Overview

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.

Detailed description

Primary Progressive Aphasia (PPA) is a neurodegenerative disorder that selectively affects language comprehension and/or production, with initial preservation of other cognitive domains. As tDCS has not been extensively studied in PPA, the investigators will measure both short- and long-term effects of stimulation in patients with this neurodegenerative disorder that affects specific language regions. Previous research suggests that neurostimulation with tDCS can safely induce changes in neural plasticity that can lead to long-term restoration of synaptic function. Thus, individually targeted stimulation to structurally preserved but dysfunctional regions may be able to produce behavioral improvements in primary progressive aphasia (PPA).

TDCS is a method of stimulating the brain that does not require any sedation or surgery. TDCS is a technique that sends a weak electrical current through the scalp to stimulate the brain areas below. The information gained from this research study will aid in the development of therapies to improve language in people with neurological conditions that affect language use.

TDCS will be applied over the activated area identified with the functional magnetic resonance imaging (fMRI) fMRI-localizer task. This approach will allow for individually optimized tDCS electrode placement. It will also account for potential inter-participant variability in the brain atrophy and language organization

Summary of study sequence and procedures:

Week 1: Baseline screening, language testing, one event-related brain potential (EEG-ERP) session Weeks 2: fMRI session to determine most effective treatment Weeks 3-4: tDCS with Language Treatment Part 1 Weeks 5 and 6: rest-period, post-treatment assessment Weeks 7 to 8: TDCS with Language Treatment Part 2 Weeks 9 and 10: rest period, post-treatment assessment 2-month follow-up, language assessment, one MRI scan, one EEG-ERP session

Interventions

  • Combination product tDCS + language therapy
    In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
  • Combination product sham TDCS + language therapy
    sham control will be applied with language therapy to the same regions as active TDCS.

Primary outcome measures

  • Mean change from baseline scores on the Arizona Phonological Battery [Time frame: through study completion, an average of 1 year]
  • Mean change from baseline scores on the naming task [Time frame: through study completion, an average of 1 year]
  • Mean change from baseline scores on the language probe task before and after each session [Time frame: through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • diagnosed with PPA by neurologist or speech-language pathologist
  • speech-language deficit arising from PPA
  • native speaker of English Language or equivalent
  • adequate vision (normal or corrected to normal)
  • adequate hearing

Exclusion criteria

  • meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders.
  • highly magnetizable metallic implants, including certain dental work
  • neurological disorders besides the ones of interest for the study (e.g., epilepsy)
  • Multiple Sclerosis
  • Parkinson's Disease
  • contraindications for MRI
  • pacemakers
  • metallic cardiac pumps
  • valves
  • magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.
  • clinically significant claustrophobia
  • severe systemic disease (e.g., renal failure)
  • poor health
  • pregnancy
  • epileptic activity in the past 12 months
  • family history of epilepsy or other seizure disorders
  • brain surgery in the past
  • metallic skull plates or implants
  • skin lesions or skull damage
  • excessive use of alcohol or drugs
  • premorbid psychiatric disease affecting communication
  • severe non-linguistic cognitive disturbances impeding language therapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of Arizona — Tucson

Identifiers

NCT: NCT04920318 · 2103570362

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗